Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2.

scientific article

Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/HMG/DDS057
P932PMC publication ID3349422
P698PubMed publication ID22357653
P5875ResearchGate publication ID221854296

P50authorTed M. DawsonQ56046960
Darren J MooreQ87693446
Dagmar GalterQ30505381
Michael K LeeQ30505385
Valina L. DawsonQ30505388
P2093author name stringJuan C Troncoso
Saskia Biskup
Olga Pletnikova
Alessandra Musso
Sandra Gellhaar
João Paulo L Daher
P2860cites workDopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2.Q21135493
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activityQ22254785
Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic miceQ24293070
Localization of LRRK2 to membranous and vesicular structures in mammalian brainQ24318643
Genome-wide association study reveals genetic risk underlying Parkinson's diseaseQ24646654
Mutation in the alpha-synuclein gene identified in families with Parkinson's diseaseQ27860459
alpha-Synuclein locus triplication causes Parkinson's diseaseQ27860533
α-Synuclein in Lewy bodiesQ27860680
Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy.Q48592402
LRRK2 is expressed in areas affected by Parkinson's disease in the adult mouse brain.Q48645605
Aβ deposition is associated with enhanced cortical α-synuclein lesions in Lewy body diseasesQ54964999
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathologyQ28131833
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's diseaseQ28292932
Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019SQ28589899
The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementiaQ29547174
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's diseaseQ29547175
Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's diseaseQ29614900
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control studyQ29614953
Kinase activity is required for the toxic effects of mutant LRRK2/dardarinQ29620478
Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic miceQ30476254
R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice.Q30483115
Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.Q33594388
Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's diseaseQ33754793
Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).Q33757616
The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activityQ35235888
The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's diseaseQ36325701
The biology and pathobiology of LRRK2: implications for Parkinson's diseaseQ37207742
Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neuronsQ37294051
Molecular mechanisms of alpha-synuclein neurodegenerationQ37309838
Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease.Q37313530
Mendelian forms of Parkinson's diseaseQ37376999
Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body diseaseQ37402225
The genetics of Parkinson's syndromes: a critical reviewQ37472412
Parkinsonism, Lrrk2 G2019S, and tau neuropathologyQ40216459
Biochemical and pathological characterization of Lrrk2.Q40324969
New stereological methods for counting neuronsQ40843719
A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2.Q43501182
Distribution of PINK1 and LRRK2 in rat and mouse brainQ45859017
Lrrk2 and alpha-synuclein are co-regulated in rodent striatumQ46369373
Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death.Q46884563
Lrrk2 and Lewy body diseaseQ46912096
LRRK2 expression linked to dopamine-innervated areasQ46987594
Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brainQ48162781
Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brainQ48372083
P433issue11
P921main subjectneurodegenerationQ1755122
SynucleinQ24767155
P304page(s)2420-2431
P577publication date2012-02-21
P1433published inHuman Molecular GeneticsQ2720965
P1476titleNeurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2.
P478volume21

Reverse relations

cites work (P2860)
Q33835006Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats
Q48003270Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease
Q64886210Alpha-synuclein suppresses mitochondrial protease ClpP to trigger mitochondrial oxidative damage and neurotoxicity.
Q27310355Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease.
Q56567928Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease
Q30653185Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration
Q55516103D409H GBA1 mutation accelerates the progression of pathology in A53T α-synuclein transgenic mouse model.
Q54441670Dangerous duet: LRRK2 and α-synuclein jam at CMA
Q33825413Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents
Q37119983Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases
Q36325667Evolution of Neurodegeneration
Q47582501G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain.
Q37096048G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.
Q37583402Genetic insights into sporadic Parkinson's disease pathogenesis
Q27303568High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain
Q38044434Insights into LRRK2 function and dysfunction from transgenic and knockout rodent models
Q51082143Interaction of LRRK2 and α-Synuclein in Parkinson's Disease
Q41539639LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model
Q54977439LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
Q98177378LRRK2 and Protein Aggregation in Parkinson's Disease: Insights From Animal Models
Q97066874LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson's Disease?
Q26861279LRRK2 as a Potential Genetic Modifier of Synucleinopathies: Interlacing the Two Major Genetic Factors of Parkinson's Disease
Q64966531LRRK2 modifies α-syn pathology and spread in mouse models and human neurons.
Q38253871LRRK2 pathobiology in Parkinson's disease
Q48264748Lack of exacerbation of neurodegeneration in a double transgenic mouse model of mutant LRRK2 and tau.
Q35925767Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration
Q38009436Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease
Q55240777Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease.
Q35152964Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and α-synuclein aggregation
Q39137358Mechanisms of LRRK2-dependent neurodegeneration: role of enzymatic activity and protein aggregation.
Q48239635Mechanisms of Mutant LRRK2 Neurodegeneration
Q38021865Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences
Q30573776Mitochondrial permeability transition pore regulates Parkinson's disease development in mutant α-synuclein transgenic mice
Q64122238Modeling G2019S-LRRK2 Sporadic Parkinson's Disease in 3D Midbrain Organoids
Q39206443Models of LRRK2-Associated Parkinson's Disease
Q24318474Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies
Q55122127Mutations in LRRK2 amplify cell-to-cell protein aggregate propagation: a hypothesis.
Q96219413Neuron-autonomous susceptibility to induced synuclein aggregation is exacerbated by endogenous Lrrk2 mutations and ameliorated by Lrrk2 genetic knock-out
Q33856698Novel AAV-based rat model of forebrain synucleinopathy shows extensive pathologies and progressive loss of cholinergic interneurons
Q37707932Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology
Q33991769Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration
Q99716681Pathogenic LRRK2 requires secondary factors to induce cellular toxicity
Q21131229Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism
Q64265990Rab GTPases as Physiological Substrates of LRRK2 Kinase
Q27007413Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic
Q38111307The Neurobiology of LRRK2 and its Role in the Pathogenesis of Parkinson’s Disease
Q52374337The Role of LRRK2 in Neurodegeneration of Parkinson Disease
Q64859135The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease

Search more.